MedTrace Logo

A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

NCT03126799 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2022-04-06

No results posted yet for this study

Summary

Korean data of treating EGFR mutation positive NSCLC patients with Erlotinib and Bevacizumab is significantly necessary for developing new standard treatment in first-line therapy in Korean EGFR mutant NSCLC patients.

In this study, The investigators will investigate the efficacy and safety of Erlotinib and Bevacizumab combination compare to Erlotinib alone in Korean EGFR-mutant NSCLC patients.

Conditions

  • EGFR Positive Non-small Cell Lung Cancer

Interventions

DRUG

Erlotinib plus Bevacizumab

Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks

DRUG

Erlotinib

Erlotinib 150mg, po, daily, Q weeks

Sponsors & Collaborators

  • Roche Korea co.,Ltd.

    collaborator UNKNOWN

  • National Cancer Center, Korea

    lead OTHER_GOV

Principal Investigators

  • Ji-Youn Han, Ph.D · National Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-01
Primary Completion
2021-12-31
Completion
2023-07-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03126799 on ClinicalTrials.gov